HistoIndex to Present AI-based Stain-free Pathology Findings at AASLD 2024

HistoIndex, a leading innovator in artificial intelligence (AI) and stain-free digital pathology, is set to present its latest research and AI-based analysis advancements at the 75th Liver Meeting® (TLM) 2024. This prominent event, organized by the American Association for the Study of Liver Diseases (AASLD), will take place from November 15th to 19th in San Diego, California. The conference will gather top scientists, clinicians, and industry professionals in the field of hepatology.

HistoIndex will showcase its pioneering methods for assessing liver fibrosis regression and progression. Their AI-enabled approach significantly enhances the detection, quantification, and assessment of various liver conditions, including Metabolic Dysfunction-Associated Steatohepatitis (MASH) and fibrosis. Given the growing global incidence of liver diseases, these presentations are crucial in demonstrating how HistoIndex’s technology can provide accurate, reproducible, and interpretable data from liver biopsies, thereby addressing current challenges.

As a front-runner in AI-based analysis utilizing stain-free digital pathology, HistoIndex will present twelve abstracts from phase 2b and phase 3 clinical trials at TLM 2024. These trials cover four different mechanisms of action (MOA) in MASH. Dr. Dean Tai, Chief Scientific Officer at HistoIndex, emphasized the significance of these findings. They highlight the transformative role of AI in advancing liver disease diagnosis, prognosis, and personalized treatment. HistoIndex’s technology has demonstrated utility in studies focused on cirrhotic MASH, differentiation between pediatric and adult MASH, predicting clinical outcomes, and understanding hepatocellular carcinoma recurrence in chronic hepatitis B patients.

Key highlights from HistoIndex at TLM 2024 include multiple oral and poster sessions:

1. Oral Presentation on Sunday, November 17th:
- Title: AI-based digital pathology shows that denifanstat improves multiple parameters of fibrosis and reduces progression to cirrhosis in MASH patients with F2/F3 fibrosis - results of the FASCINATE-2 study
- Presenter: Dr. Mary Rinella

2. Poster Presentations:
- Friday, November 15th:
- Title: Application of artificial intelligence algorithm as a vascular evaluation tool for intra-stage assessment in cirrhotic patients with metabolic dysfunction-associated steatotic liver disease
- Presenter: Dr. Zhengxin Li

- Title: The role of steatosis and fibrosis parameters in predicting hepatocellular carcinoma recurrence in chronic hepatitis B patients
- Presenter: Dr. Ke Yin

- Saturday, November 16th:
- Title: Comparative evaluation of zonal fibrosis patterns in pediatric and adult metabolic dysfunction-associated steatohepatitis biopsies using Second Harmonic Generation/Two Photon Excitation-based qFibrosis analysis
- Presenter: Dr. Naim Alkhouri

- Title: Evaluating the impact of weight changes on histological patterns of liver fibrosis in MASH: implications for spatial interrogation
- Presenter: Dr. Kutbuddin Akbary

- Title: Evaluation of the consistency and heterogeneity of adjacent sections in fibrosis assessment using AI-based qFibrosis in virtual liver needle biopsies
- Presenter: Dr. Yayun Ren

- Title: Independent validation of second harmonic generation/two photon excitation imaging and artificial intelligence-based SNOF index for metabolic dysfunction-associated steatohepatitis cirrhosis assessment
- Presenter: Dr. Kutbuddin Akbary

- Title: Stain-free digital pathology imaging provides microarchitecturally-resolved insights into scar evolution and histological injury, allowing direct clinical outcome prediction in metabolic dysfunction-associated steatotic liver disease
- Presenter: Dr. Jonathan Fallowfield

- Sunday, November 17th:
- Title: Fibrosis regression after Tirzepatide treatment of non-cirrhotic MASH for 52 weeks occurs in a zone-dependent manner
- Presenter: Dr. Arun Sanyal

- Title: Validating pre-identified morphological baseline features for predicting fibrosis progression in MAESTRO-NASH
- Presenter: Dr. Jörn Schattenberg

- Monday, November 18th (Late Breaking Posters):
- Title: AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with Efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study
- Presenter: Dr. Mazen Noureddin

- Title: Efruxifermin significantly reduced the proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study
- Presenter: Dr. Mazen Noureddin

Additionally, HistoIndex will host a breakfast meeting on November 15th, offering clinicians, researchers, and industry partners an opportunity to discuss the transformative potential of AI-based analysis using stain-free digital pathology in MASH clinical trials and its role in routine clinical care post-drug approvals.

Conference attendees are invited to visit HistoIndex at Booth #1225. Here, they can experience the company’s Second Harmonic Generation (SHG) technology and AI-enabled analytics through interactive demonstrations. Knowledgeable representatives will be available to engage with attendees and explore potential partnerships.

Founded in 2010, HistoIndex leads in providing stain-free, automated imaging solutions for visualizing and quantifying fibrosis in biological tissues. Their innovative tools combine biophotonic technology and AI-based analysis to improve fibrosis assessment and drug efficacy, accelerating research and transforming medical standards.